Drugs & Targets

Drugs & Targets

Wistar Institute, Pennsylvania Biotechnology Center, Baruch S. Blumberg Institute collaborate to support regional biotech startups

The Wistar Institute, the Pennsylvania Biotechnology Center, and the Baruch S. Blumberg Institute formed a collaboration to accelerate the advancement of “bench to bedside” biomedical research discoveries in Pennsylvania, New Jersey, and Delaware by collectively supporting the seeding, launching, and maturation of life science startups.
Drugs & Targets

EC approves Breyanzi for R/R DLBCL

The European Commission approved Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor T-cell therapy, for the treatment of adult patients with diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. 
Drugs & Targets

FDA accepts sBLA and EMA validates Reblozyl as first-line treatment of anemia in lower risk MDS

FDA accepted the supplemental Biologics License Application sBLA and the European Medicines Agency has validated the Type II Variation Application for Reblozyl (luspatercept-aamt) to expand its current indication to include treatment of anemia without previous use of erythropoiesis-stimulating agents in adult patients with very low- to intermediate-risk myelodysplastic syndromes who may require red blood cell transfusions.